Claudio Bordignon

MOLMED S.p.A. is a leading Italian biotechnology company focused on research, development and production of new therapeutic compounds in the area of molecular medicine. The company has an established track record of developing and manufacturing cell banks and viral vectors for clinical studies. The MOLMED OptiStem team involves specialists from the areas of Development, Production, Quality Control, Quality Assurance and Regulatory Affairs.